The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
AbbVie reported a Q1 earnings beat powered by robust sales growth of its immunology drugs Skyrizi and Rinvoq. According to reports, the performance of these newer treatments successfully mitigated the revenue impact from Humira's decline, leading the company to raise its financial guidance for 2026.
Sign in to access this content
Sign InThe results highlight AbbVie's successful transition as it faces biosimilar competition for its blockbuster drug Humira. Per market data, while peers like Pfizer and Johnson & Johnson have navigated varying sector headwinds, AbbVie's ability to drive market uptake for its next-generation immunology portfolio has provided a competitive edge in revenue replacement.
With ABBV shares trading at current levels as of the May 15, 2026 close, investors are shifting focus to macroeconomic catalysts. Key upcoming events include the US Inflation Rate (CPI) data on May 12, 2026, which remains a critical indicator for broader market sentiment and sector valuations.